Tianjin Hankang Pharmaceutical Biotechnology Co. Ltd.

Primary objective: To evaluate the pharmacokinetic characteristics of acetaminophen injection after single administration of 325 mg and 1000 mg, and after multiple administration of 500 mg in healthy Chinese subjects. Secondary objective: To investigate the safety of acetaminophen injection.

Using 5 mg tofacitinib citrate tablets produced by Hangzhou Zhuyangxin Pharmaceutical Co., Ltd. as the test preparation and 5 mg tofacitinib citrate tablets (trade name: Shangjie®/Xeljanz®) produced by Pfizer Manufacturing Deutschland GmbH as the reference preparation, the pharmacokinetic behaviors of a single fasting/postprandial oral tofacitinib citrate tablets in healthy Chinese subjects were compared according to the relevant provisions of the bioequivalence test, and a bioequivalence evaluation was conducted to provide a basis for the registration application and clinical application of the drug.

To evaluate the pharmacokinetic characteristics of a single oral dose of the test formulation of tofacitinib citrate tablets (specification: 5 mg/tablet, Hangzhou Zhuyangxin Pharmaceutical Co., Ltd.) and the reference formulation of tofacitinib citrate tablets (Shangjie®/Xeljanz®, specification: 5 mg/tablet, Pfizer Manufacturing Deutschland GmbH) in healthy Chinese subjects under fed conditions, compare their relative bioavailability, and preliminarily evaluate the bioequivalence between the two formulations under fed conditions; 2. Explore the setting of blood collection points and washout periods to provide a reference basis for the formal trial design.